Linoladiol (Estradiol)

Estradiol binds to estrogen receptors in target cells, forming a complex that enters the nucleus and regulates gene transcription. This modulates growth and maintenance of estrogen‑dependent tissues, restoring moisture, elasticity, and systemic hormonal balance.

The specific dose and regimen of Linoladiol are determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual response. Dosage details are provided on the prescription label.

Estradiol is generally contraindicated during pregnancy because it may affect fetal development. Use while breastfeeding should be evaluated by a healthcare professional, as estrogen can pass into breast milk and influence milk production.

To request Linoladiol, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Linoladiol delivers estradiol via a vaginal route, providing localized action with lower systemic exposure compared with oral or transdermal estrogen products. This can reduce certain systemic side effects while effectively treating vaginal atrophy and local menopausal symptoms.

Linoladiol should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve product stability and potency.

Linoladiol is applied intravaginally according to the prescribing information. The patient inserts the supplied dose into the vagina using the provided applicator or device, typically once daily or as directed by the healthcare provider.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, endometrial hyperplasia or carcinoma, severe allergic reactions, and hepatotoxicity. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Linoladiol is contraindicated in women with known estrogen‑dependent tumors, active or past thromboembolic disease, uncontrolled hypertension, liver disease, or those who are pregnant. It should also be used with caution in breast cancer survivors and individuals with a history of cardiovascular events.